GRI Bio Inc
GRI1.305USD
-0.015-1.16%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
685.43KCap. mercado
PérdidaP/E TTM
Más Datos de GRI Bio Inc Compañía
GRI Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic, and autoimmune disorders. Its therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as an oral therapeutic for the treatment of idiopathic pulmonary fibrosis (IPF). Its product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. The Company is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) or lupus and multiple sclerosis (MS).
Información de la empresa
Símbolo de cotizaciónGRI
Nombre de la empresaGRI Bio Inc
Fecha de salida a bolsaFeb 10, 2021
Director ejecutivoDr. W. Marc Hertz, Ph.D.
Número de empleados3
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 10
Dirección2223 Avenida De La Playa
CiudadLA JOLLA
Bolsa de valoresLondon Stock Exchange
PaísUnited States of America
Código postal92037
Teléfono16194001171
Sitio Webhttps://www.gribio.com/
Símbolo de cotizaciónGRI
Fecha de salida a bolsaFeb 10, 2021
Director ejecutivoDr. W. Marc Hertz, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Albert Agro, Ph.D.
Dr. Albert Agro, Ph.D.
Chief Medical Officer
Chief Medical Officer
111.00
--
Dr. Vipin Kumar Chaturvedi, Ph.D.
Dr. Vipin Kumar Chaturvedi, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. David Szekeres
Mr. David Szekeres
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Camilla V. Simpson
Ms. Camilla V. Simpson
Independent Director
Independent Director
--
--
Mr. Roelof Rongen
Mr. Roelof Rongen
Independent Director
Independent Director
--
--
Ms. Jenene Thomas
Ms. Jenene Thomas
IR Contact Officer
IR Contact Officer
--
--
Mr. David C. Baker
Mr. David C. Baker
Director
Director
--
--
Ms. Leanne M. Kelly
Ms. Leanne M. Kelly
Chief Financial Officer
Chief Financial Officer
--
--
Dr. W. Marc Hertz, Ph.D.
Dr. W. Marc Hertz, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Albert Agro, Ph.D.
Dr. Albert Agro, Ph.D.
Chief Medical Officer
Chief Medical Officer
111.00
--
Dr. Vipin Kumar Chaturvedi, Ph.D.
Dr. Vipin Kumar Chaturvedi, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. David Szekeres
Mr. David Szekeres
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Camilla V. Simpson
Ms. Camilla V. Simpson
Independent Director
Independent Director
--
--
Mr. Roelof Rongen
Mr. Roelof Rongen
Independent Director
Independent Director
--
--
Ms. Jenene Thomas
Ms. Jenene Thomas
IR Contact Officer
IR Contact Officer
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mié., 9 de jul
Actualizado: mié., 9 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
UBS Financial Services, Inc.
0.13%
Tower Research Capital LLC
0.05%
Hertz (Walter Marc)
0.01%
Other
99.81%
Accionistas
Accionistas
Proporción
UBS Financial Services, Inc.
0.13%
Tower Research Capital LLC
0.05%
Hertz (Walter Marc)
0.01%
Other
99.81%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
0.15%
Hedge Fund
0.05%
Individual Investor
0.02%
Other
99.78%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
20
5.55K
0.22%
-27.29K
2025Q1
19
5.33K
0.23%
-27.51K
2024Q4
20
13.78K
9.69%
-11.29K
2024Q3
27
8.71K
9.92%
-9.69K
2024Q2
28
4.88K
16.98%
+3.17K
2024Q1
27
1.68K
35.84%
+996.00
2023Q4
32
776.00
40.40%
+67.00
2023Q3
33
1.00K
63.77%
-329.00
2023Q2
39
1.48K
108.51%
+733.00
2023Q1
38
99.00
35.57%
-51.00
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
UBS Financial Services, Inc.
3.25K
0.14%
-2.18K
-40.21%
Mar 31, 2025
Tower Research Capital LLC
1.27K
0.05%
+1.07K
+520.98%
Mar 31, 2025
Hertz (Walter Marc)
249.00
0.01%
--
--
Feb 28, 2025
BlackRock Institutional Trust Company, N.A.
211.00
0.01%
-1.00
-0.47%
Mar 31, 2025
SBI Securities Co., Ltd.
117.00
0.01%
-1.00
-0.85%
Mar 31, 2025
Chaturvedi (Vipin)
111.00
0%
--
--
Feb 28, 2025
Agro (Albert)
111.00
0%
--
--
Feb 28, 2025
BofA Global Research (US)
4.00
0%
--
--
Mar 31, 2025
Altium Capital Management LP
--
0%
-851.00
-100.00%
Jun 30, 2024
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Feb 19, 2025
Merger
17<1
Feb 19, 2025
Merger
17<1
Feb 19, 2025
Merger
17<1
Feb 19, 2025
Merger
17<1
Jun 14, 2024
Merger
13<1
Jun 14, 2024
Merger
13<1
Fecha
Tipo
Relación
Feb 19, 2025
Merger
17<1
Feb 19, 2025
Merger
17<1
Feb 19, 2025
Merger
17<1
Feb 19, 2025
Merger
17<1
Jun 14, 2024
Merger
13<1
Jun 14, 2024
Merger
13<1
Jun 14, 2024
Merger
13<1
Jun 14, 2024
Merger
13<1
Jan 26, 2024
Merger
7<1
Jan 26, 2024
Merger
7<1
Ver más
